Displaying posts published in

August 2016

North Korea’s Submarine Success Pyongyang appears to have a new way to launch nuclear missiles.

North Korea often stages military provocations to distract from its political setbacks, so many predicted that it would try something after last week’s high-profile defection of senior diplomat Thae Yong-ho. But Wednesday’s launch of a ballistic missile from a submarine was more than a diversion—it was also an operational success, representing a clear advance in Kim Jong Un’s weapons arsenal.

The KN-11 missile flew some 300 miles off North Korea’s east coast, toward Japan, before falling into the sea, say U.S. and South Korean officials. That’s the longest flight by far since Pyongyang started testing its submarine launch systems in 2014. Two sub-launched missiles failed earlier this year when they blew up in midair after about 18 miles.

Pyongyang has devoted considerable resources to its nuclear and missile programs and is progressing on both fronts. Analysts in South Korea who, like their U.S. counterparts, have often underestimated North Korean capabilities, believe Pyongyang could deploy operational sub-launched missiles by 2020.

The North’s Gorae submarine, based on old Yugoslavian designs, may be relatively unsophisticated and noisy. But it could threaten South Korea, Japan and tens of thousands of U.S. troops simply by deploying around North Korea’s coast with the KN-11. The missile has an estimated top range of 550 miles.

Wednesday’s achievement follows another recent milestone for Pyongyang’s missile program. In June it successfully launched for the first time a medium-range Musudan missile from a road-mobile carrier.

The missile also reached the highest altitude the North has achieved. This is especially worrisome because the intercontinental ballistic missile Pyongyang is developing—with an estimated 10,000-mile range that could reach half the continental U.S.—uses Musudan-type engines in its initial boost phase. CONTINUE AT SITE

Anaphylactic Political Shock Sorry, Hillary. The feds are to blame for Mylan’s EpiPen monopoly.

The latest political pile-on over alleged pharmaceutical price gouging is officially underway now that Hillary Clinton joined the scrum on Wednesday. Usually these exercises are inspired by cures or important clinical innovations that happen to be expensive. The irony this time is that the target is a monopolist created by the same government that Mrs. Clinton wants to hand far more power over drugs.

In a statement, the Democrat assailed the “outrageous” cost of EpiPen, an emergency treatment for allergic reactions known as anaphylaxis, and she demanded that drug maker Mylan “immediately reduce the price.” Federal and Senate investigations are pending into these spring-loaded syringes filled with epinephrine (adrenaline) used primarily by children with life-threatening sensitivities to food or insect stings.

Mylan has raised the price of EpiPen in semiannual 10% to 15% tranches so that a two-pack that cost about $100 in 2008 now runs $500 or more after insurance discounts and coupons. Outrage seems to be peaking now because more families are exposed to drug prices directly though insurance deductibles and co-pays, plus the political class has discovered another easy corporate villain.

Still, the steady Mylan rise is hard to read as anything other than inevitable when a billion-dollar market is cornered by one supplier. Epinephrine is a basic and super-cheap medicine, and the EpiPen auto-injector device has been around since the 1970s.